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The efficacy of antibiotics to prevent collibacilosis in broiler poultry: A
protocol for a systematic review and network meta-analysis.
Abstract
Antibiotics are used in broiler poultry production both for the prevention and treatment of infectious
diseases. However, antibiotic use is a driver of antibiotic resistance. The World Health Organization has
published numerous reports urging all stakeholders concerned with both food-producing animals and
humans to establish recommended steps to enhance the prudent use of antimicrobials (WHO, 2015).
Similarly, the World Animal Health Organization has also published recommendations and position
statements regarding prudent use and risk management related to antimicrobial use in animals (OIE, 2017).
Colibacillosis is an important bacterial pathogen of poultry, and a costly disease for the industry resulting in
multimillion dollar losses annually through morbidity, mortality or carcass condemnation at slaughter.
Colibacillosis refers to any localized or systemic infection caused entirely or partly by the organism avian
pathogenic Escherichia coli (APEC). These bacteria may be isolated as the sole pathogen or contribute to a
disease complex with mixed viral and bacterial infections (Guabirara and Schouler, 2015). Two main disease
processes important in the broiler industry are early mortality and cellulitis. Early mortality is defined by
chicks under a week of age experiencing a higher than normal percentage of deaths in a flock. Early mortality
can be caused by many things, for example chilling, overheating, or dehydration, however E.coli infection, or
colibacillosis, is one of the main culprits. Colibacillosis can present with omphalitis, yolk sacculitis, enteritis,
pasty vents, pericarditis, perihepatitis, polyserositis, congested lungs, splenomegaly and darkened
proventriculus or any these combinations (Guabiraba and Schouler, 2015; Geetha and Palanivel, 2018). Many
chicks succumb to an early and severe infection or are culled due to excessive morbidity. Antibiotics are
typically used to reduce early mortality (Chauvin et al., 2005; Dziva and Stevens, 2008). Those with severe
infection are unlikely to survive, however appropriate treatment reduces transmission between birds and
improves the suitability of those with a mild infection. Not every labelled drug for E.coli is efficacious,
resistance is common (Kabir, 2010) and effectiveness can vary from flock to flock, even within a flock, with
more than one strain and more than one treatment.
Understanding the efficacy of antibiotics used to prevent colibacillosis in broiler chickens is essential to
optimizing their use; ineffective antibiotics should not be used for prevention or, if there are multiple
efficacious antibiotics, their importance to human medicine should be considered when making decisions on
antibiotic use. Systematic reviews of randomized controlled trials, and network meta-analysis to provide input
on relative antibiotic efficacy, will yield the highest level of evidence for efficacy of treatments under field
conditions (Sargeant and O’Connor, 2014).
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Introduction.	
	
Rationale:		
	
Antibiotics	are	used	in	broiler	poultry	production	both	for	the	prevention	and	treatment	of	
infectious	diseases.		However,	antibiotic	use	is	a	driver	of	antibiotic	resistance.		The	World	
Health	Organization	has	published	numerous	reports	urging	all	stakeholders	concerned	with	
both	food-producing	animals	and	humans	to	establish	recommended	steps	to	enhance	the	
prudent	use	of	antimicrobials	(WHO,	2015).		Similarly,	the	World	Animal	Health	Organization	
has	also	published	recommendations	and	position	statements	regarding	prudent	use	and	risk	
management	related	to	antimicrobial	use	in	animals	(OIE,	2017).			
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Colibacillosis	is	an	important	bacterial	pathogen	of	poultry,	and	a	costly	disease	for	the	industry	
resulting	in	multimillion	dollar	losses	annually	through	morbidity,	mortality	or	carcass	
condemnation	at	slaughter.	Colibacillosis	refers	to	any	localized	or	systemic	infection	caused	
entirely	or	partly	by	the	organism	avian	pathogenic	Escherichia	coli	(APEC).		These	bacteria	may	
be	isolated	as	the	sole	pathogen	or	contribute	to	a	disease	complex	with	mixed	viral	and	
bacterial	infections	(Guabirara	and	Schouler,	2015).	Two	main	disease	processes	important	in	
the	broiler	industry	are	early	mortality	and	cellulitis.	Early	mortality	is	defined	by	chicks	under	a	
week	of	age	experiencing	a	higher	than	normal	percentage	of	deaths	in	a	flock.	Early	mortality	
can	be	caused	by	many	things,	for	example	chilling,	overheating,	or	dehydration,	however	E.coli	
infection,	or	colibacillosis,	is	one	of	the	main	culprits.	Colibacillosis	can	present	with	omphalitis,	
yolk	sacculitis,	enteritis,	pasty	vents,	pericarditis,	perihepatitis,	polyserositis,	congested	lungs,	
splenomegaly	and	darkened	proventriculus	or	any	these	combinations	(Guabiraba	and	
Schouler,	2015;	Geetha	and	Palanivel,	2018).	Many	chicks	succumb	to	an	early	and	severe	
infection	or	are	culled	due	to	excessive	morbidity.	Antibiotics	are	typically	used	to	reduce	early	
mortality	(Chauvin	et	al.,	2005;	Dziva	and	Stevens,	2008).	Those	with	severe	infection	are	
unlikely	to	survive,	however	appropriate	treatment	reduces	transmission	between	birds	and	
improves	the	suitability	of	those	with	a	mild	infection.	Not	every	labelled	drug	for	E.coli	is	
efficacious,	resistance	is	common	(Kabir,	2010)	and	effectiveness	can	vary	from	flock	to	flock,	
even	within	a	flock,	with	more	than	one	strain	and	more	than	one	treatment. 
	
Understanding	the	efficacy	of	antibiotics	used	to	prevent	colibacillosis	in	broiler	chickens	is	
essential	to	optimizing	their	use;	ineffective	antibiotics	should	not	be	used	for	prevention	or,	if	
there	are	multiple	efficacious	antibiotics,	their	importance	to	human	medicine	should	be	
considered	when	making	decisions	on	antibiotic	use.	Systematic	reviews	of	randomized	
controlled	trials,	and	network	meta-analysis	to	provide	input	on	relative	antibiotic	efficacy,	will	
yield	the	highest	level	of	evidence	for	efficacy	of	treatments	under	field	conditions	(Sargeant	
and	O’Connor,	2014).			
	
Objectives:		The	objective	of	this	protocol	is	to	describe	the	methods	for	a	systematic	review	–	
network	meta-analyses	to	address	the	question:	“What	is	the	efficacy	of	antibiotics	to	prevent	
colibacillosis	in	broiler	chickens?”		 
			The	specific	PICO	elements,	which	will	define	the	eligibility	criteria,	are	as	follows:	
i. Population:	Broiler	poultry.		
ii. Intervention:	Antibiotics	licensed	for	use	in	chickens	in	ovo,	by	injection,	in	feed,	or	in	the	
water	at	doses	consistent	with	therapeutic	or	prophylactic	use.		Eligible	antibiotics	include	
any	antibiotic	for	use	in	treating	or	preventing	colibacillosis	in	poultry	included	in	the	OIE	
list	of	antimicrobial	agents	of	veterinary	importance1	(see	also	appendix	1).	
iii. Comparator:		Placebo,	untreated	control	group,	or	an	alternative	antibiotic	treatment.	
iv. Outcomes:		The	outcomes	of	interest	are	mortality,	Feed	Conversion	Ratio	(FCR),	
condemnations	due	to	colibacillosis,	and	total	antibiotic	use.	
                                                
1 OIE	list	of	antimicrobial	agents	of	veterinary	importance	(May	2015)	available	at:	
http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/Eng_OIE_List_antimicrobials_May201
5.pdf 
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Methods	
	
Eligibility	criteria:		In	addition	to	eligibility	criteria	inherent	in	the	PICO	elements	described	
above,	eligibility	includes	publication	in	English.		Both	journal	articles	and	other	forms	of	
research	reports	are	eligible,	provided	they	report	the	results	of	a	primary	research	study	with	a	
concurrent	comparison	group	using	an	eligible	study	design	and	with	a	full	text	of	more	than	
500	words.			
	
Study	designs	eligible:		Controlled	trials	with	natural	disease	exposure	(individual	or	cluster	
allocated)	will	be	eligible	for	inclusion,	although	we	will	document	the	number	of	controlled	
trials	with	deliberate	disease	challenge	and	analytical	observational	studies	at	full	text	
screening	and	also	will	identify	the	antibiotic	interventions	(i.e.	licensed	antibiotics	used	at	
labelled	doses)	and	whether	any	of	the	outcomes	of	interest	were	assessed	for	studies	of	these	
designs.		
	
Information	sources:			
	
We	will	conduct	the	literature	search	in	a	range	of	relevant	bibliographic	databases	and	other	
information	sources	containing	both	published	and	unpublished	literature.	Table	1	presents	the	
resources	to	be	searched.		
	
Table	1:		Databases	and	information	sources	to	be	searched	
	
Database	/	information	source	 Interface	/	URL	
MEDLINE	 PubMed	
CAB	Abstracts		 CAB	Interface	
Science	Citation	Index		 Web	of	Science	
Conference	 Proceedings	 Citation	 Index	 –	
Science	
Web	of	Science	
Agricola	 Proquest	
	
Most	of	the	key	poultry	conferences	provide	short	abstracts	(<500	words)	in	their	conference	
proceedings,	which	do	not	provide	the	detail	necessary	to	include	in	a	systematic	review.		
However,	the	Western	Poultry	Disease	Conference	provides	full	papers.		Therefore,	one	
reviewer	will	hand-search	title	/	abstracts	for	potentially	relevant	study	reports.		Any	articles	
thus	identified	will	be	entered	into	DistillerSR	for	level	2	screening	by	2	reviewers.		
	
A	 single	 reviewer	 will	 also	 search	 the	 USDA	 FDA	 FOI	 requests	 for	 antibiotics	 registered	 for	
prophylactic	use	for	collibacillosis	in	broilers	in	the	USA.		A	single	reviewer	will	hand-search	the	
reference	lists	of	all	included	studies	for	any	eligible	studies	that	may	have	been	missed	by	the	
database	searches.	
 4 
	
Search	strategy:			
	
A	Science	Citation	Index	(Web	of	Science)	search	strategy	designed	to	identify	studies	of	
antibiotic	use	to	prevent	collibacillosis	in	broilers	is	presented	in	Table	2.	The	search	strategy	
employs	a	multi-stranded	approach	to	maximize	sensitivity.		The	conceptual	structure	is	as	
follows:	
	
•	 Broilers;		
AND	
•	 Antibiotics;	
AND	
• Collibacillosis	
AND	
• Disease	prevention	(as	opposed	to	treatment)	
	
	
Table	2:	Search	strategy	to	identify	studies	of	antibiotics	for	the	prevention	of	collibacillosis	in	
broilers	using	Science	Citation	Index	(Web	of	Science)	
	
#1				TS	=	(Chicken*	OR	Poultry*	OR	flock*	OR	gallus*	OR	broiler*)	 							193,683	
	
#2				TS	=	(medicat*	OR	antimicrobial*	OR	"anti-microbial*"	OR	antibiotic*	OR	"anti-biotic*"	OR	
antibacterial*	OR	"anti-bacterial*"	OR	antiinfect*	OR	"anti-infect*"	OR	bacteriocid*	OR	
bactericid*	OR	microbicid*	OR	"anti-mycobacteri*"	OR	antimycobacteri*)								796,347									
	
#3				TS	=	(apramycin	OR	amoxicillin	OR	Avilamycin	OR	enrofloxacin	OR	Neomycin	OR	Neomicin	
OR	salinomycin	OR	salinomicin	OR	spectinomycin	OR	Sulfaquinoxaline	OR	ceftiofur	OR	
gentamycin	OR	gentamicin	OR	lincomycin	OR	oxytetracycline	OR	Bacitracin	OR	
Sulfadimethoxine	OR	Sulfaquinoxaline	OR	Virginiamycin	OR	Chlortetracycline	OR	Tylosin	OR	
Tetracycline	OR	Trimethoprim	OR	Virginiamycin	OR	Sulfamethoxazole)										108,922	
	
#4					TS	=	(Apralan	OR	Baytril	OR	paracillin	OR	Garasol	OR	Lincosol	OR	Lincomix	OR	Coban	OR	
Monteban	OR	Neo-chlor	OR	neo-tetramed	OR	NeoMed	OR	Neotet	OR	oxy	OR	oxysol	OR	sacox	
OR	posistac	OR	coxistac	OR	Sulforal	OR	Sulfadived	OR	di-methox	OR	Onycin	OR	tetra	OR	
tetramed	OR	Stafac	OR	“Super	Booster”	OR	Uniprim	OR	Tylan)							59,298					
	
#5		TS	=	(collibacillosis	OR	coli	OR	Escherichia	OR	coliform	OR	colisepticaemia	OR	colisepticemia	
OR	coligranuloma	OR	Hjarre’s	OR	“air	sac	disease”	OR	cellulitis	OR	peritonitis	OR	osteomyelitis	
OR	“brittle	bone	disease”	OR	peritonitis	OR	salpingitis	OR	synovitis	OR	omphalitis	OR	enteritis		
OR	“hemorrhagic	septicemia”	OR	“chronic	respiratory	disease”	OR	“swollen	head	syndrome”	
OR	“venereal	colibacillosis”	OR	“coliform	cellulitis”	OR	“yolk	sac	infection”	)										582,217	
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#6		TS	=	(prophyla*	OR	metaphyla*	OR	"meta-phyla*"	OR	“mass	treatment”	or	“mass	
medication”	or	“blanket	medication”	or	“blanket	treatment”	OR	prevent*	OR	“in	feed”	OR	“in-
feed”	OR	“in-water”	OR	“in	water”	OR	“medicated”	OR	“in	ovo”)							1,827,320				 
 
	
#1	AND	(#2	OR	#3	OR	#4)	AND	#5	AND	#6									619		
	
The	search	strategies	will	not	be	limited	by	date,	language,	or	publication	type.			
	
We	will	 conduct	 searches	using	each	database	 listed	 in	 the	protocol,	 translating	 the	 strategy	
appropriately	to	reflect	the	differences	in	database	interfaces	and	functionality.			
	
Study	records:	
	
			 Data	management:		We	will	download	the	results	of	searches	in	a	tagged	format,	load	them	
into	bibliographic	software	(EndNote)	and	de-duplicate	the	citations.	The	de-duplicated	search	
results	will	be	uploaded	into	online	systematic	review	software	(DistillerSR®,	Ottawa,	ON,	
Canada),	and	de-duplication	will	be	repeated	in	DistillerSR	using	an	internal	program.	Reviewers	
will	have	training	in	epidemiology	and	in	systematic	review	methods.		Prior	to	both	abstract	and	
full-text	screenings,	data	extraction,	and	risk	of	bias	assessment,	the	reviewers	assigned	to	each	
step	will	undergo	training	to	ensure	consistent	data	collection	using	the	forms	created	in	
DistillerSR®.		
	
				Selection	process:			In	the	first	round	of	screening,	abstracts	and	titles	will	be	screened	for	
eligibility.	Two	reviewers	will	independently	evaluate	each	citation	for	relevance	using	the	
following	questions:	
1)	Is	this	a	primary	study	evaluating	the	use	of	one	or	more	antibiotics	to	prevent	colibacillosis	
in	broilers?		
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
2) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
3) Is	the	full	text	available	in	English?		[language	of	publication	can	be	included	as	a	field	in	
DistillerSR]	
YES	(include	for	full	text	screening),	NO	(EXCLUDE),	UNCLEAR	(include	for	full	text	
screening)	
	
Citations	will	be	excluded	if	both	reviewers	responded	“no”	to	any	of	the	questions.		Any	
disagreements	will	be	resolved	by	consensus.		If	consensus	cannot	be	reached,	the	article	will	
be	marked	as	“unclear”	and	will	advance	to	full	text	screening.		A	pre-test	will	be	conducted	by	
all	reviewers	on	the	first	250	abstracts	to	ensure	clarify	of	questions	and	consistency	of	
understanding	of	the	questions.	
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Following	title/abstract	screening,	eligibility	will	be	assessed	through	full-text	screening,	using	
the	questions	included	below.	Two	reviewers	will	independently	evaluate	the	full	text	articles,	
with	any	disagreements	resolved	by	consensus.	If	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.	A	pre-test	will	be	conducted	by	all	reviewers	on	the	first	10	full	texts	to	
ensure	clarify	of	questions	and	consistency	of	understanding	of	the	questions.	
1) Is	the	full	text	available	with	>	500	words?		
YES	(neutral	response),	NO	(EXCLUDE)	
2) Is	the	full	text	available	in	English?		
YES	(neutral	response),	NO	(EXCLUDE)	
3) Eligible	population:	Does	the	study	evaluate	broilers?		
YES	(neutral	response),	NO	(EXCLUDE)	
4) Eligible	intervention:	Does	the	study	assess	the	use	of	one	or	more	of	the	antibiotics	of	
interest	for	the	PREVENTION	of	collibacillosis	in	broilers?	
								YES	(neutral	response),	NO	(EXCLUDE)	
5) Are	at	least	one	of	the	following	outcomes	described:	mortality,	FCR,	condemnations	due	
to	colibacillosis,	or	total	antibiotic	use.	
YES	(neutral	response),	NO	(EXCLUDE	
6) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE)	
7) Eligible	study	design:	Is	the	study	a	controlled	trial	with	natural	disease	exposure?	
Yes	(moves	to	data	extraction	stage),	
No,	the	study	is	a	controlled	trial	with	deliberate	disease	induction	(indicate	the	
antibiotic(s)	evaluated,	but	exclude	from	data	extraction)	
No,	the	study	is	an	observational	study	(indicate	the	antibiotic(s)	evaluated	but	
exclude,	from	data	extraction)	
	
	
			Data	collection	process:		Data	will	be	extracted	by	two	reviewers	working	independently.		Any	
disagreements	will	be	resolved	by	consensus	or,	if	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.		Authors	will	not	be	contacted	to	request	missing	data	or	to	clarify	
published	results.		A	form	for	data	extraction	will	be	created	for	this	review	in	DistillerSR®	and	
pre-tested	on	4	full	text	articles	to	ensure	question	clarity.	
	
Data	items:		
	
Study	level	data	to	be	extracted	include:	
• Country	 where	 trial	 was	 conducted	 (if	 not	 stated,	 use	 country	 affiliation	 of	
corresponding	author)	
• Commercial	versus	research	flocks	
• Number	of	flocks	enrolled	in	study	
• Year(s)	the	study	was	conducted	
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• Months	of	data	collection	
• Stage	of	production	where	intervention	was	applied	
• Stage	of	production	where	outcome	was	evaluated	
	
Arm	level	data	collected:	
• Antibiotic	name(s)	
• Dose	/	route	/	frequency	of	administration	
• Unit	of	allocation	(e.g.	room,	flock)	
• Description	of	comparison	group		
• Number	of	birds	enrolled	
• Number	of	pens	/	rooms	/	flocks	enrolled	
• Number	of	animals	/	pens	/	rooms	/	flocks	lost	to	follow	up	
• Number	of	animals	/	pens/	rooms	/	flocks	analyzed	
• Any	additional	concurrent	treatments	given	to	both	intervention	groups.	
• The	 approach	 used	 in	 the	 analysis	 to	 account	 for	 non-independent	 observations	 (not	
applicable,	not	reported,	random	effects,	GEE,	other)	
	
Outcomes	and	prioritization:			
	
• Mortality,	
• FCR,	
• Condemnations	at	slaughter	due	to	collibacillosis,	
• Total	antibiotic	use.	
	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
Outcome	data	to	be	collected:	
	
1) Mortality	
a. Level	at	which	outcome	data	were	measured	(animal	/	room	/	flock)	
b. Time	period	for	assessing	outcome	
	
2) Feed	Conversion	Ratio	
a. Age	/	weight	at	slaughter	
b. Level	at	which	the	outcomes	data	were	measured	(animal	/	room	/	flock)	
	
3) Condemnation	due	to	collibacillosis	
a. Case	definition	
b. Age	/	weight	at	slaughter	
	
4) Total	antibiotic	use	
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a. Measure	used	to	define	outcome	
b. Time	period	for	assessing	outcome	
c. Antibiotic(s)	used	
	
For	each	outcome,	we	will	extract	the	possible	metrics	in	the	following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• Variance	components.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	outcome	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	with	the	
signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-2.0	for	
clustered	RCTs	and	individual	RCTs	will	be	used	depending	on	the	study	design	(Higgins	et	al.,	
2016).	These	tools	are	available	at	https://sites.google.com/site/riskofbiastool/welcome/rob-2-
0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	outcome.		Network	meta-analysis	will	use	the	approach	
described	by	NICE	Decision	Support	Unit	technical	document	(Dias	et	al.,	2014;	O’Connor	et	al.,	
2013;	O’Connor	et	al.,	2016).	The	approach	to	reporting	will	use	the	PRISMA-	NMA	
(http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	priori	
sub-group	analyses	will	be	conducted	for	randomized	versus	non-randomized	trials.		
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	antibiotic-
comparator	combinations	where	there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	
we	will	use	approaches	to	assessing	publication	bias	in	the	network	of	evidence	using	
previously	proposed	approaches	(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
	
Confidence	in	cumulative	evidence:		The	quality	of	evidence	for	each	outcome	will	be	assessed	
using	 the	 approach	 proposed	 by	 GRADE	 (GRADE,	 2015,	 Puhan	 et	 al.,	 2014),	 while	 also	
considering	the	nature	of	the	network	meta-analysis	 (Jansen	et	al.,	2011).	 	 If	 feasible,	we	will	
use	the	framework	from	the	CINeMA	platform	for	conveying	the	impact	of	risk	of	bias	on	the	
network	performance.				
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Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
antibiotics	used	to	prevent	collibacillosis	in	poultry.		Results	will	be	helpful	for	veterinarians	and	
poultry	producers	when	making	evidence-informed	decisions	regarding	treatment	options	to	
reduce	disease	and	mortality,	and	potentially	reduce	the	need	to	use	antibiotics	to	treat	
collibacillosis.		The	results	also	will	be	helpful	for	identifying	specific	gaps	in	knowledge	related	
to	the	efficacy	of	prophylactic	antibiotics	for	collibacillosis	to	target	additional	research.	
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Appendix	1:		Antibiotics	approved	for	use	for	collibacillosis	in	poultry,	with	trade	names	and	
labelling	information.	
	
	
Antibiotic	
(AVIAN)	 Market	name		 Dose		
	 	 	
Amoxicillin	
Paracillin®	SP	(Pr)	(Merck	Animal	
Health),	Amoxicillin	SP	(Pr)	(Bio	
Agri	Mix)		
10-20	mg	(8-16	mg	amoxicillin	
trihydrate)/kg	b.w.	daily,	for	3-5	
consecutive	days.		
Avilamycin	
Paracillin®	SP	(Pr)	(Merck	Animal	
Health),	Amoxicillin	SP	(Pr)	(Bio	
Agri	Mix)		
0.15-0.3	kg/1,000	kg	feed	(15-30	
ppm	avilamycin).	Feed	as	sole	
ration	for	21d	during	risk	period	
Bacitracin	
Paracillin®	SP	(Pr)	(Merck	Animal	
Health),Amoxicillin	SP	(Pr)	(Bio	
Agri	Mix)		
Broilers:	0.5	kg/999.5	kg	
complete	feed	(55	mg/kg).	Feed	
continuously	to	market	weight.	
Ceftiofur	
(sodium)	
Paracillin®	SP	(Pr)	(Merck	Animal	
Health),Amoxicillin	SP	(Pr)	(Bio	
Agri	Mix)		
Day-old	chicks:	0.08-0.2	mg	
ceftiofur/chick	in	the	neck.	One	
mL	of	50	mg/mL	reconstituted	
solution	will	treat	~250-625	day-
old	chicks.	
Chlortetracycline	
Paracillin®	SP	(Pr)	(Merck	Animal	
Health),Amoxicillin	SP	(Pr)	(Bio	
Agri	Mix)		
Broiler,	layer	and	replacement	
chickens:	Add	1	kg/tonne	[110	
mg/kg	(0.011%)]	of	complete	
feed.		
Feed	continuously	as	sole	ration	
from	onset	of	symptoms	for	at	
least	one	month	or	until	a	few	
days	after	symptoms	disappear.	
Gentamicin	 Garasol®	Injection	(100	mg/mL)	(Intervet/Merck	Animal	Health)	
Each	day-old	chick:	Inject	S.C.	in	
neck	with	0.2	mg	gentamicin	in	a	
0.2	mL	dose	(diluted	with	saline	
solution).	
	
Coccivac®-B52	(Intervet/Merck	
Animal	Health)	
Healthy	birds	1d	of	age:	Spray	
cabinet:	Dilute	1,000	dose	vial	
with	210	mL	distilled	water.	
Each	box	of	100	chicks	receives	
21	mL	of	vaccine	solution.	
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Lincomycin	
(hyrdrochloride)	
	
	
	
	
	
	
Lincomycin	Hydrochloride	Soluble	
Powder	(Rx)	(Huvepharma)	
	
	
	
	
	
	
Broilers:	64	mg	lincomycin/gal	
drinking	water	for	7d.	
	
	
Lincosol	Soluble	Powder	(Rx)	
(Med-Pharmex)	
Broilers:	64	mg	lincomycin/gal	
drinking	water	for	7d.		
	
Lincomycin	Soluble	Powder	(Bio	
Agri	Mix)	
1	jar/2,000	L	drinking	water	(16	
mg	antibiotic	activity/L).		
	 Lincomix®	Soluble	Powder	(Zoetis)	
At	first	sign	of	disease,	
administer	at	following	dosage	
as	sole	source	of	drinking	water	
for	7	consecutive	days.80	g	
soluble	powder	will	medicate	
2,000	L	water	or	1	level	scoop	
(4.7	g)/120	L	water	(16	mg	
antibiotic	activity/L).Stock	
solution:	80	g/8	L	(1	level	
scoop/470	mL)	water	in	a	clean	
glass	or	plastic	container,	mix,	
and	dispense	1	L	stock	
solution/250	L	drinking	water.	
	
	
	
	
	
	
	
	
Neomycin	
(sulfate)	
	
Neomycin	325	(Pr)	(Vetoquinol)	
	
	
	
	
Flock	treatment:	As	soon	as	
symptoms	are	observed,	give	for	
3-5d.	
Day-old	to	2	weeks:	20	g	
powder/225	L	water	OR	100	g	
powder	(1	pouch)/1,125	L	
water.		
2	weeks	to	adulthood:	40	g	
powder/225	L	water	OR	200	g	
powder	(2	pouches)/1,125	L	
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water.	
	 Neo-Chlor®	(Pr)	(Vetoquinol),		
100	g,	10	kg	sizes:	Dissolve	100-
200	g	(1-2	pouches)	powder/225	
L	water	for	3-5d.		
400	g:	Dissolve	400-800	g	(1-2	
pouches)/900	L	water	for	3-5d.		
Automatic	proportioner:	Set	to	
distribute	30	mL/4	L	water	(1	
oz/gal).	Prepare	stock	solution	
by	dissolving	400-800	g	(1-2	
pouches)/6.75	L	water	to	
medicate	900	L	water.	
	 Neo-Tetramed	(Medprodex)	
Dissolve	400-800	g	(1-2	
pouches)/900	L	water	for	3-5d.		
	 NeoMed	325	(Medprodex)	
Day-old	to	2	weeks:	20	g/225	L	
of	water	OR	100	g/1,125	L	of	
water.	2	weeks	to	adulthood:	40	
g/225	L	of	water	OR	200	g/1,125	
L	of	water.		
	
Neotet	Soluble	Concentrate	
(Dominion)	
100	g	in	200-400	L	of	drinking	
water	for	3d.		
Oxytetracycline	 Oxy	250	(Medprodex)	 1	g/5	L	water	OR	100	g/500	L	
drinking	water	for	3-5d.		
	 Oxysol-62.5	(Pr)	(Vetoquinol)	
Dissolve	4	g	powder/5	L	water	
OR	400	g	(1	pouch)	powder/500	
L	drinking	water	and	give	for	3-
5d.	
Oxytetracycline	
HCI	
Oxytetracycline	HCI	Soluble	
Powder	1000	(Bio	Agri	Mix)	
100	g/1,350	L	drinking	water	for	
3-4d.		
Salinomycin	
(sodium)	
	
	
	
Sacox®	60	(Huvepharma),	Bio-
Cox®	60	Granular	(Huvepharma)	
	
	
	
Broiler,	roaster	and	replacement	
(breeder	and	layer)	chickens:		
40-60	g/ton	(0.0044-0.0066%).	
Feed	continuously	as	sole	ration.	
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Salinomycin	60	Premix	(Bio	Agri	
Mix),	Posistac®	6%	Premix	
(Phibro),	Coxistac®	6%	Premix	
(Phibro)	
Thoroughly	mix	1000	g	(1.0	kg)	
Salinomycin	60	Premix	with	999	
kg	complete	feed	to	obtain	a	
finished	feed	containing	60	
mg/kg	(60	ppm)	salinomycin	
sodium.	Feed	continuously	as	
sole	ration	up	until	slaughter.	
	
Coxistac®	12%	Granular	(Phibro),	
Sacox®	120	(Huvepharma	AD)	
Broiler	chickens:	Thoroughly	mix	
500	g	Coxistac	12%	Granular	
with	1,000	kg	complete	feed	to	
obtain	a	medicated	feed	with	a	
salinomycin	sodium	
concentration	of	0.0060%	(60	
mg/kg).	Can	be	prepared	in	the	
form	of	meal	or	pellets.	Feed	
continuously	as	sole	ration	up	to	
marketing.	
Sulfadimethoxine	
Sulfadimethoxine	Concentrated	
Solution	12.5%	(Rx)	(VetOne),	
Sulforal	(Rx)	(Med-Pharmex),	
Sulfadived™	12.5%	Solution	(Rx)	
(Vedco),	Di-Methox®	
Concentrated	Solution	12.5%	(Rx)	
(AgriLabs)	
Use	0.05%	concentration.		
Add	1	oz	(30	mL)	to	2	gal	water	
or	25	oz/50	gal	water.		
Treat	for	6	consecutive	days.		
	
Sulfadimethoxine	107g	Powder	
(Rx)	(VetOne),	Di-Methox®	Soluble	
Powder	(Rx)	(AgriLabs),	Sulfasol	
(Rx)	(Med-Pharmex),	Sulfasol	(Rx)	
(Med-Pharmex)	
Use	0.05%	concentration.		
Add	1	packet/50	gal	water.		
Treat	for	6	consecutive	days.		
Stock	solution:	Add	5	packets/2	
gal	water.		
Sulfaquinoxaline	 Sulfaquinoxaline	19.2%	Liquid	Concentrate	(Dominion)	
https://cdmv.cvpservice.com/pr
oduct/view/1181072?key=dosag
e	
Tetracycline	
Onycin	1000	(Pr)	(Vetoquinol),	
Tetra	1000	(Dominion),	Tetramed	
250	and	1000	(Medprodex),	Oxy	
250	(Medprodex)	
1	g/20	L	of	water	OR	100	g/2000	
L	of	drinking	water,	for	3-5d.	For	
automatic	proportioner:	Set	to	
distribute	30	mL/4	L	drinking	
water	(1	oz/gal	U.S.).	Prepare	
stock	solution	by	dissolving	25	g	
powder/4	L	water.	This	will	
medicate	500	L	drinking	water.	
	
Oxytetracycline	HCI	Soluble	
Powder	1000	(Bio	Agri	Mix)	
100	g/1,350	L	drinking	water	for	
3-4d.		
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	 Tetracycline	250	(Vetoquinol)	
400	g:	Dissolve	1	g/5	L	or	400	g	
(1	pouch)/2,000	L	drinking	
water,	for	3-5d.		
10	kg:	Dissolve	1	g/5	L	or	100	
g/500	L	drinking	water,	for	3-5d.		
	
	
	
Oxysol-62.5	(Pr)	(Vetoquinol)	
	
	
Dissolve	4	g	powder/5	L	water	
OR	400	g	(1	pouch)	powder/500	
L	drinking	water	and	give	for	3-
5d	
Tylosin	(tartrate)	
	
	
	
Tylan®	Soluble	(Rx)	(Elanco)	
	
	
	
broiler	chickens:	851-1,419	
mg/gal	(225-375	ppm)	in	
drinking	water.	Administer	
medicated	drinking	water	for	a	
single	5d	period.	
Broiler	chickens:	100-150	mg/L,	
depending	on	severity	of	
infection.		
	
	
	
Tylosin	Soluble	Powder	(Bio	Agri	
Mix)	
Mix	0.4-
0.6g/4L	
water,	Treat	
5d	
	
Tylan™	Soluble	(Pr)	(Elanco	
(Novartis))	
	
Broiler	chickens	(drinking	
water):	Treat	for	5d	at	not	<100	
mg/L	(0.4	g/4	L)	and	not	more	
than	150	mg/L	(0.6	g/4	L)	
depending	on	severity	of	
outbreak.		
	
	
Tylosin	
(Phosphate)	
	
	
Tylosin	40	(Bio	Agri	Mix)	
	
	
125	kg/tonne	complete	diet	(11	
g	tylosin).		
	
Tylan™	100	Premix	(Pr)	(Elanco	
(Novartis))	
Broiler	chickens:	0.91	kg	(200	g	
tylosin)/tonne	complete	feed.		
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Virginiamycin	
	
	
	
	
	
Virginiamycin	44	Premix	(Bio	Agri	
Mix),	Stafac®	44	(Phibro)	
	
Broilers:	Mix	0.5	kg	(22	g	
virginiamycin)/tonne	complete	
feed	to	provide	1	mg/kg	
b.w./day.	Feed	continuously	as	
sole	ration	from	weaning	to	
market	weight.	
	 Stafac®	22	(Phibro)	
Broilers:	Mix	1	kg	(22	g	
virginiamycin)/tonne	complete	
feed	to	provide	1	mg/kg	
b.w./day.	Feed	continuously	as	
sole	ration	from	day	1	to	market	
weight.	
	
Stafac®	500	(Phibro)	
Mix	44	g/tonne	(22	g	
virginiamycin)	complete	feed.	
This	will	provide	1	mg/kg	
b.w./day.		
	
